Trial Profile
Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers: the ARMANI Phase III Trial
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Ramucirumab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Levofolinic acid; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms ARMANI
- 03 Sep 2021 Planned End Date changed from 1 Oct 2019 to 1 Dec 2021.
- 03 Sep 2021 Planned primary completion date changed from 1 Oct 2019 to 1 Dec 2021.
- 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology